Role of Inferior Vena Cava Dispensability Index in Predicting Hypotension of Cement Syndrome in Hip Replacement Surgery Under General Anaesthesia

June 22, 2026 updated by: Ain Shams University
The aim of the study is to evaluate ICV distensibility index for predicting the incidence of hypotension following cementation in orthopedic hip replacement surgery in patient undergoing general anaesthesia

Study Overview

Status

Active, not recruiting

Detailed Description

Preoperative Settings:

Patients scheduled for elective hip replacement surgeries involving cementation at Ain Shams University Surgery Hospital will be identified and those meeting the inclusion criteria will be approached and enrolled after providing informed consent.

Patients will be confirmed to have fasted for 8 hours before surgery. Medical history will be taken, examinations performed, and laboratory results will be reviewed. A wide bore intravenous line (18-gauge) will be secured, and standard monitoring (ECG, blood pressure measurement, and pulse oximetry) will be applied.

Baseline blood pressure, heart rate, and mean arterial pressure will be recorded.

Intraoperative procedure:

To induce general anaesthesia, we will be using fentanyl (1-2 μg/kg), propofol (1.5-2 mg/kg) and non-depolarizing muscle relaxants (rocuronium or cis-atracurium) according to age, weight, chronic organ function and the needs of the surgery.

All patients are monitored continuously using ECG, pulse oximetry and capnography starting from the beginning of manual ventilation. Ventilatory parameters adjusted to PCO2 <40 mmHg (respiratory rate 12 breaths per minute,), with a tidal volume of 6 to 8 ml/kg, positive end-expiratory pressure (PEEP) of 6 cmH2O and inspired oxygen fraction (FiO2) of 50.

Noninvasive blood pressure measurements (mean arterial pressure (MAP) are obtained at 10 min intervals although the operation, an additional measurement is obligatory 2 min after induction, drug administration and during measurement of IVC-DI and 5 min pre- and post-cementing for 15 min, all measurements will be performed in the semi-recumbent position (head elevated 30°).

The inferior vena cava will be visualized in B-mode using ultrasound machine with Low-frequency curvilinear probe (2-5 MHz) or phased-array probe while patient in supine position the probe will be placed in subxiphoid (subcoastal) area, just below the sternum (from a longitudinal paramedian subxiphoid view). IVC can be differentiated from the aorta utilizing pulse wave Doppler. With M-mode imaging, done 2 to 3 cm distant to the right atrium, The last section of the vein, which is proximal to the hepatic vein inflow and 0.5-3 cm from the right atrium, will be selected, with Use of the callipers to measure the maximum IVC diameter (Dmax) during inspiration and the minimum IVC diameter (Dmin) during expiration. Then the IVC distensibility index is calculated and recorded using the formula: IVC distensibility index = [(maximum diameter on inspiration-minimum

diameter on expiration)/minimum diameter on expiration (Lujan Varas et al, 2015). All IVC measurements are taken post intubation 3 times and the mean value recorded. Patients will be divided into two groups.

Group A: those who develop hypotension post cementation. Group B: those who do not develop hypotension post cementation. In the study Hypotension will be defined as MAP < 60 mmHg or a decrease in SBP by > 20% from baseline. In case of persistent mean arterial pressure less than 55 mmHg, a 6 mg dose of ephedrine will be titrated. After two doses of ephedrine, another fluid bolus of 5 ml/kg will be given, followed by another dose of ephedrine until hypotension is corrected.

The primary outcome:

Cut off value of IVC-DI at which we can predict the incidence of hypotension following cementing in orthopedic surgery.

Secondary outcomes Intra-operative hemodynamic, the need of vasoactive drug administration, and the amount of fluid administered.

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Abbassia
      • Cairo, Abbassia, Egypt, 00202
        • Ain Shams University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients will be selected from primary care clinic who are scheduled for Hip Replacement Surgery

Description

Inclusion Criteria:

  • participants must be 18 years of age or older and provide written consent. Patients scheduled for elective hip replacement surgery under general anaesthesia with an American Society of Anesthesiologists (ASA) physical status of I or III based on preoperative assessment.

Exclusion Criteria:

  • ▪ Patient refusal to participate.

    • ASA status IV or above.
    • Patients with BMI more than 30 kg/m².
    • Pre-existing hypotension, cardiac disease (such as heart failure or coronary artery disease), pulmonary disease (such as chronic obstructive pulmonary disease), renal disease (such as chronic kidney disease), hepatic disease (such as cirrhosis), coagulopathy or bleeding disorders, pregnancy or lactation, severe intra-operative blood loss requiring blood transfusion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cut off value of IVC-DI at which we can predict the incidence of hypotension following cementing in orthopedic surgery.
Time Frame: All IVC measurements are taken 10 minutes post intubation
Cut off value of IVC-DI at which we can predict the incidence of hypotension following cementing in orthopedic surgery.
All IVC measurements are taken 10 minutes post intubation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intra-operative hemodynamic(blood pressure)
Time Frame: At 10 minutes intervals all through the operation, an additional measurement is obligatory 2 minutes after induction, drug administration and during measurement of IVC-DI and 5 minutes pre- and post-cementing for 15 minutes
In the study Hypotension will be defined as MAP < 60 mmHg or a decrease in SBP by > 20% from baseline.
At 10 minutes intervals all through the operation, an additional measurement is obligatory 2 minutes after induction, drug administration and during measurement of IVC-DI and 5 minutes pre- and post-cementing for 15 minutes
The need of vasoactive drug administration
Time Frame: Post cement insertion for 30 minutes
In case of persistent(>5minutes) mean arterial pressure less than 55 mmHg, a 6 mg dose of ephedrine will be titrated.
Post cement insertion for 30 minutes
The Amount of Fluid administered.
Time Frame: Post cement insertion for 30 minutes
After two doses of ephedrine, another fluid bolus of 5 ml/kg will be given, followed by another dose of ephedrine until hypotension is corrected.
Post cement insertion for 30 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Azza Mohamed Lotfy Youssef Nasr, Assistant Professor Phd, Ain Shams University
  • Study Director: Aya Ali Mahmoud Bayoumy, Lecturer Phd, Ain Shams University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 20, 2025

Primary Completion (Estimated)

June 20, 2026

Study Completion (Estimated)

June 20, 2026

Study Registration Dates

First Submitted

May 20, 2026

First Submitted That Met QC Criteria

June 22, 2026

First Posted (Actual)

June 25, 2026

Study Record Updates

Last Update Posted (Actual)

June 25, 2026

Last Update Submitted That Met QC Criteria

June 22, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypotension and Shock

Clinical Trials on Ultrasound measurement of IVC

3
Subscribe